Neurocrine Biosciences Cash Flow Statement
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences free cash flow
In fiscal 2025, Neurocrine Biosciences generated $782.7 million of operating cash flow and spent $34.0 million on capital expenditures. That left free cash flow of $748.7 million, a free-cash-flow margin of 26.2% of revenue. Free cash flow was up 34.4% from the prior year's $557.2 million.
Neurocrine Biosciences returned $167.7 million to shareholders through share repurchases, equal to 22% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 478.60M | 341.30M | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M | -142.54M | -141.09M |
| Net Income growth (YoY) | +40.23% | +36.68% | +61.62% | +72.43% | -78.00% | +1000.81% | +75.26% | — | — | — |
| Depreciation & Amortization | 26.00M | 23.50M | 17.80M | 15.10M | 10.90M | 8.60M | 7.40M | 4.02M | 2.40M | 1.45M |
| Stock-Based Compensation | 217.90M | 195.50M | 194.30M | 173.10M | 134.20M | 100.00M | 75.30M | 58.10M | 42.52M | 28.46M |
| Change in Working Capital | -65.60M | -15.50M | -34.90M | -50.20M | 25.90M | -14.30M | -21.60M | -4.40M | -4.81M | 4.29M |
| Operating Cash Flow | 782.70M | 595.40M | 389.90M | 339.40M | 256.50M | 228.50M | 147.00M | 101.40M | -94.33M | -106.18M |
| Capital Expenditures | -34.00M | -38.20M | -28.30M | -16.50M | -23.40M | -10.90M | -14.70M | -24.80M | -6.94M | -4.11M |
| Investing Cash Flow | -264.40M | -126.80M | -467.10M | -177.10M | -130.20M | 4.10M | -211.10M | -242.90M | -251.25M | 112.95M |
| Share Repurchases | -167.70M | -300.00M | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | -38.30M | -486.70M | 65.30M | -234.30M | 27.40M | -157.80M | 32.40M | 29.50M | 516.65M | 2.39M |
| Net Change in Cash | 480.00M | -18.10M | -11.60M | -73.30M | 153.70M | 74.80M | -31.70M | -112.00M | 171.06M | 9.16M |
| Free Cash Flow | 748.70M | 557.20M | 361.60M | 322.90M | 233.10M | 217.60M | 132.30M | 76.60M | -101.27M | -110.29M |
This table shows 10 annual periods of Neurocrine Biosciences's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NBIX's reporting calendar. What is a cash flow statement?